The Left Atrial Appendage Closure (LAAC) is an alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation (AF).
Implanting this device is intended for the percutaneous, transcatheter closure of the left atrial appendage (LAA). Patients with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism, are suitable for warfarin and seek a non-pharmacologic alternative to warfarin may be eligible for a LAAC Device.
By closing off the LAA, a thin, sack-like appendix arising from the left side of the heart that is believed to be the source of a majority of stroke-causing blood clots in people with non-valvular AF1, the risk of stroke may be reduced and, over time, patients may be able to stop taking warfarin.
Implanting the LAAC Device is a one-time procedure that usually lasts about an hour and is typically conducted with general anesthesia. It is implanted through a femoral access via a trans-septal approach by using a catheter-based delivery system. The device is designed to permanently close off the LAA, believed to be the source of a majority of strokecausing blood clots, and thereby avoid the migration of emboli to the brain. Following the procedure, patients typically need to stay in the hospital for 24 hours.
WATCHMAN LAAC Implant
Left Atrial Appendage Closure with the WATCHMAN device is a safe and effective alternative to long-term oral anticoagulants. Learn more about the WATCHMAN device and how the implant procedure works, click here.